BioLife Solutions (NASDAQ:BLFS) was upgraded by TheStreet from a “c” rating to a “b-” rating in a report released on Friday, TheStreetRatingsTable reports.
Several other equities analysts have also issued reports on the company. ValuEngine raised BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Saturday, November 23rd. Zacks Investment Research cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. BidaskClub raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Monday, November 25th. Maxim Group set a $26.00 price objective on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Northland Securities lifted their target price on shares of BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.00.
NASDAQ BLFS opened at $15.77 on Friday. BioLife Solutions has a 12 month low of $9.15 and a 12 month high of $22.44. The stock has a market cap of $342.57 million, a P/E ratio of 112.64, a P/E/G ratio of 20.94 and a beta of 1.33. The stock’s fifty day moving average price is $16.54 and its 200-day moving average price is $17.66. The company has a current ratio of 6.49, a quick ratio of 5.33 and a debt-to-equity ratio of 0.01.
Several institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in BioLife Solutions in the 2nd quarter worth about $30,000. Alpine Woods Capital Investors LLC purchased a new position in BioLife Solutions in the 2nd quarter worth about $170,000. Morgan Stanley raised its position in BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after buying an additional 1,713 shares during the last quarter. Menta Capital LLC purchased a new position in BioLife Solutions in the 2nd quarter worth about $202,000. Finally, Charles Schwab Investment Management Inc. bought a new position in BioLife Solutions during the 2nd quarter valued at about $283,000. 50.22% of the stock is currently owned by institutional investors.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Read More: What is a Buy-Side Analyst?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.